Key result
Carbamazepine pretreatment cuts ivabradine bioavailability by ~80%.
Why the study?
Ivabradine is a novel heart rate-lowering agent and the study aimed to evaluate a possible pharmacokinetic interaction between ivabradine and carbamazepine in healthy volunteers.
Does carbamazepine alter the pharmacokinetics of ivabradine in healthy volunteers?
Does carbamazepine alter the pharmacokinetics of ivabradine in healthy volunteers?
Effect estimate: 80% reduction in bioavailability
Absolute Event Rate: 3.69% vs 16.25%
Carbamazepine significantly reduces the bioavailability of ivabradine by approximately 80%, indicating a clinically significant drug-drug interaction.
No takes yet. Share an insight, caveat, or question.
Alerts to major interaction risk with carbamazepine; leaves open effects on efficacy and safety in patients.
Vlase et al. (2010) studied Healthy volunteers. Carbamazepine vs. Ivabradine alone was evaluated on Mean peak plasma concentration (Cmax) of ivabradine (80% reduction in bioavailability). Carbamazepine pretreatment significantly lowered the bioavailability of ivabradine by about 80%, reducing mean peak plasma concentrations from 16.25 ng/mL to 3.69 ng/mL.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: